Life Sciences Archives - Page 2 of 21 - Becker's Hospital Review

New HHS program aims to speed clinical trials | Oral GLP-1 delivers 11% weight loss | 11K bottles of blood pressure medication recalled | Tampa General sues Eli Lilly | 5 new drugs in shortage

Clinical trial reform, GLP-1 results, a medication recall and new drug shortages. July 8, 2026 1. HHS launches Operation TrailBlazer to speed up clinical trials: 5 notes Full story 2. Oral GLP-1 delivers up to 11.3% weight loss: 4 study…

Amgen recalls 934K+ bottles of heart, kidney drugs | Cancer drug shortages raise rationing concerns | AstraZeneca to pay $34M over Medicaid kickbacks | Immunotherapy approvals dropped 40% last year | GLP-1s linked to slower biological aging

Drug recalls and shortages mount, plus a new case for GLP-1s. July 1, 2026 1. Amgen recalls 934K+ bottles of heart, kidney drugs Full story 2. AstraZeneca to pay Texas $34M over alleged Medicaid kickbacks Full story 3. Central Florida…

Ebola cases jump 38% in 1 week | FDA approves 1st single-dose flu drug | 8 GLP-1 findings to know | 46 highest-paid healthcare CEOs | GLP-1s may improve fertility

Ebola outbreak updates, a drug milestone and the latest on GLP-1s. June 24, 2026 1. FDA approves 1st single-dose generic flu drug Full story 2. Ebola outbreak is 3x larger at 4 weeks than any before: 6 updates Full story 3. NYU…

Lilly wins injunction in $200M fraud lawsuit | What next-gen GLP-1s are trying to solve | Nonprofit secures access to experimental cancer drug | Lilly's oral GLP-1 outperforms rival in trial | Inside the escalating 340B rebate battle

From fraud to breakthroughs: the week’s biggest life sciences moves. June 17, 2026 1. Court grants Lilly injunction in lawsuit alleging $200M fraud scheme Full story 2. Next-gen GLP-1s target 3 key limitations: Report Full story 3. Precision genomics at…

FDA clears 1st AI drug development tool | The new cancer pill getting leaders' attention | 7 conditions GLP-1s treat beyond weight loss | Study flags infection risk with antibody therapies | Anthropic AI model cuts drug design time

AI drug tools, a new cancer pill, GLP-1 surprises and an antibody caution. June 10, 2026 1. What leaders need to know about the breakthrough pancreatic cancer pill Full story 2. FDA accepts letter of intent for 1st AI drug development tool Full…

FDA approves 1st COVID pill | Mounjaro beats rival GLP-1s in trial | Cancer drug shows efficacy across 6 tumor types | GLP-1s may cut breast cancer risk | Lilly gives hospitals 340B ultimatum

GLP-1 and cancer breakthroughs, plus a pharma showdown with hospitals. June 3, 2026 1. FDA approves 1st oral COVID-19 prevention drug Full story 2. Mounjaro outperforms other GLP-1s in early Type 2 diabetes treatment: Study Full story 3. Is your…

GLP-1s linked to lower cancer incidence | Parkinson's drug halted after trial fail | FDA approves 1st chronic HDV treatment | Can Epic get any bigger? | 3 drug safety fronts to watch

Cancer prevention, a midstage trial failure and an FDA first. May 27, 2026 1. GLP-1s and cancer outcomes: What new research shows Full story 2. Parkinson’s drug development halted after midstage trial failure Full story 3. $20K–$60K per infection: Why…

Novo says Wegovy pill beats Lilly's orforglipron | Trump bought Eli Lilly stock during coverage push | Melanoma drug rejected again | Generic Ozempic could be delayed | FDA approves 1st-in-class blood pressure drug

Novo vs. Lilly, Trump’s stock trade, a melanoma setback and an Ozempic delay. May 20, 2026 1. Novo says Wegovy pill trumps Lilly’s orforglipron in key measures Full story 2. FDA rejects melanoma drug, again Full story 3. How WakeMed,…

GLP-1s linked to higher breast cancer survival | Mounjaro dethrones Keytruda as world's top-selling drug | The peptide craziness hits US | Pancreatic cancer drug extends survival 8 months | 7 new drugs in shortage

Mounjaro dethrones Keytruda and GLP-1s may help cancer patients live longer. May 13, 2026 1. GLP-1s linked to higher breast cancer survival: 3 notes Full story 2. Mounjaro surpasses Keytruda as top-selling drug Full story 3. Revenue leakage starts before…

The next GLP-1 boom | Mark Cuban's 8-part healthcare playbook | New Alzheimer's treatment approved | FDA approves 1st gene therapy for hearing loss | US drug shortages on the rise

GLP-1 and gene therapy breakthroughs, plus a drug shortage warning. May 6, 2026 1. The next phase of the GLP-1 boom Full story 2. FDA approves new Alzheimer's agitation treatment Full story 3. Advocate Health, Mayo Clinic and 515+ speakers…